NurExone Biologic Inc has been accepted into the BioFab Startup Lab, part of the Advanced Regenerative Manufacturing Institute (ARMI) and its BioFabUSA program, reinforcing the company’s presence in the US regenerative manufacturing sector.

The federally-supported initiative provides early-stage biotechnology companies with access to specialised facilities, mentorship and biomanufacturing resources to accelerate the translation of regenerative innovations into scalable, commercially viable production.

Dr Lior Shaltiel, CEO of NurExone, said: “Biofabrication is becoming the industrial foundation of next-generation medicine. Federal support for programs like this reflects how US priorities are expanding beyond semiconductors and clean energy toward biomanufacturing. The ARMI ecosystem and infrastructure have the potential to yield longer-term commercial benefits for the Company in GMP-grade US exosome production and to accelerate the time to market for our products.”

NurExone’s US subsidiary, Exo-Top Inc, is advancing plans to establish a GMP-compliant facility dedicated to naive exosome production. Participation in ARMI’s program is expected to enhance the company’s ability to meet regulatory standards and support collaborations with strategic partners.

Biofabrication involves using living cells and biological materials to manufacture tissues and therapeutic products, bridging the gap between scientific discovery and industrial-scale production. The technology is considered a foundation for the next generation of regenerative medicine, enabling production of complex therapies that were previously difficult to scale.

The ARMI BioFab Startup Lab provides six months of targeted support for early-stage companies, including access to facilities, mentoring from industry experts, and connections with both academic and commercial partners. The initiative is part of BioFabUSA, which is federally funded through the US Economic Development Administration and aims to position biomanufacturing as a strategic capability within the national advanced manufacturing framework.

Recent federal initiatives, including a White House Bioeconomy Executive Order, highlight biomanufacturing as a growing priority alongside semiconductors and clean energy. Participation in ARMI allows companies such as NurExone to leverage US infrastructure for regenerative therapies, accelerate time to market and strengthen operational capabilities in the competitive regenerative medicine landscape.